Name: Latest research reports of Ipca Laboratories Ltd. authored by Motilal Oswal and published by - Trendlyne research reports.
Item: Ipca Laboratories Ltd.
Rating: 5
Author: Motilal Oswal

Ipca Laboratories Ltd.

NSE: IPCALAB | BSE: 524494 | ISIN: INE571A01038 | Industry: Pharmaceuticals
| Strong Performer, Getting Expensive

1507.8000 -20.00 (-1.31%)

NSE Jan 13, 2026 15:31 PM

29.07% Gain from 52W Low

Volume: 147.0K

Ipca Laboratories Ltd.

13 Nov 2025, 12:00AM

1507.80

-1.31%

Beat on estimates; DF/API drive earnings

Buy: Ipca Laboratories Ltd.

Target

Motilal Oswal

Ipca Laboratories (IPCA) delivered slightly better-than-expected revenue in 2QFY26, while EBITDA/PAT beat our estimates by 18%/22%.

Ipca Laboratories Ltd. is trading above all available SMAs